ARA-290: selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/ara-290 1. Heij L, Niesters M, Swartjes M, et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study Molecular Medicine. DOI: https://doi.org/10.2119/molmed.2012.00332 PMID: 23168581 Source: https://pubmed.ncbi.nlm.nih.gov/23168581/ Verification: Abstract / bibliographic record. 2. Dahan A, Dunne A, Swartjes M, et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density Molecular Medicine. DOI: https://doi.org/10.2119/molmed.2013.00122 PMID: 24136731 Source: https://pubmed.ncbi.nlm.nih.gov/24136731/ Verification: Abstract / bibliographic record. 3. Brines M, Dunne AN, van Velzen M, et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes Molecular Medicine. DOI: https://doi.org/10.2119/molmed.2014.00215 PMID: 25387363 Source: https://pubmed.ncbi.nlm.nih.gov/25387363/ Verification: Full text. 4. Dahan A, Dunne A, Swartjes M, et al. (2016). Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density Molecular Medicine. DOI: https://doi.org/10.2119/molmed.2013.00122.erratum PMID: 28059429 Source: https://pubmed.ncbi.nlm.nih.gov/28059429/ Verification: Full text. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.